Interleukin-6 and tumor necrosis factor-α as biochemical markers of heart failure: A head-to-head clinical comparison with B-type natriuretic peptide

Journal of Cardiovascular Medicine

Volumn 10, Issue 10, 2009, Pages 758-764

  Boffa, Giovanni M ^a   Zaninotto, Martina ^a   Sartor, Riccardo ^a   Mion, Monica ^a   Berton, Alessandra ^a   Pasqualetto, Cristina ^a   Razzolini, Renato ^a   Plebani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

B type natriuretic peptide; heart failure; interleukin 6; prognosis; tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOCHEMISTRY; CAUSE OF DEATH; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FLUID RETENTION; FOLLOW UP; HEART ATRIUM PRESSURE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN BLOOD LEVEL; RELIABILITY; UNIVARIATE ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349119505     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832ce8e2     Document Type: Article

References (30)

1. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-585.
2. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90:464-470. (Pubitemid 38406929)
3. Kruger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40:718-722.
4. Lee SC, Stevens TL, Sandberg SM, Nelson SM, Jougasaki M, Redfield MM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association Classification class during the outpatients treatment of heart failure. J Cardiac Fail 2002; 90:149-154.
5. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:391-398.
6. Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206.
7. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 77:723-727.
8. Maeda K, Takayoshi T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular enddiastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-832.
9. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nichols MG. Brain natriuretic factor: regional plasma concentration and correlation with hemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-417.
10. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39:1623-1629.
11. MacGowan GA, Mann DL, Kormos RL, Felman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79:1128-1131.
12. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278-1283.
13. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25:292-299.
14. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from Vesnarinone trial. Circulation 2001; 103:2055-2059.
15. Rauchhaus M, Doehner W, Francis DP. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
16. Kell R, Haunstetter A, Dengler TJ, Zugk C, Kubler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients. Comparison with other potential predictors of prognosis. Eur Heart J 2002; 23:70-78.
17. Jortani SA, Prabhu SD, Valdes R Jr. Strategies for developing biomarkers of heart failure. Clin Chem 2004; 50:265-278.
18. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148-2159.
19. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116:e99-e109.
20. Maisel A. The coming of age of natriuretic peptides: the emperor does have clothes. J Am Coll Cardiol 2006; 47:61-64.
21. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593.
22. Gwechenberger M, Hulsmann M, Berger R, Graf S, Springer C, Stanek B, et al. Interleukin-6 and B-type natriuretic peptide are independent predictors of worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 2004; 23:839-844.
23. Birner C, Ulucan C, Fredersdorf S, Rihm M, Löwel H, Stritzke J, et al. Head to head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: superiority of BNP. Cytokine 2007; 40:89-97.
24. Ratnasamy C, Kinnamon DD, Liphultz SE, Rusconi P. Association between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 2008; 155:527-533.
25. McLachlan CS, Mossop P. Laevosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure? Eur J Heart Fail 2006; 8:216-217.
26. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Cardiac Fail 2008; 14:61-74.
27. Mabuchi N, Tsutamoto T, Wada A, Ohnishi M, Maeda K, Hayashi M, et al. Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in patients with congestive heart failure. Chest 2002; 121:1195-1202.
28. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant 1998; 17:356-362.
29. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004; 94:957-960.
30. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.